Literature DB >> 1462918

The treadmill exercise score revisited: coronary arteriographic and thallium perfusion correlates.

A S Iskandrian1, M Ghods, H Helfeld, B Iskandrian, V Cave, J Heo.   

Abstract

The treadmill exercise score has been used to stratify patients into low-, moderate-, and high-risk groups. This score is derived from ST segment depression, angina, and exercise duration. To determine the coronary arteriographic and exercise thallium perfusion correlates of the score, we examined the extent of coronary artery disease and exercise single photon emission computed thallium-201 results in 834 patients for whom cardiac catheterization data were available. Of those, 174 had no coronary artery disease, 195 had one-vessel, 246 had two-vessel, and 219 had three-vessel disease. Based on the treadmill exercise score, 369 were in the low-risk, 384 in the moderate-risk, and 81 in the high-risk group. The extent of coronary artery disease was 2.1 +/- 1 diseased vessels in the high-risk, 1.7 +/- 1 in the moderate, and 1.4 +/- 1.1 in the low-risk group (p < 0.01). The extent of the thallium abnormality (maximum number of abnormal segments 120/patient) was 10 +/- 6 in the high-risk, 7 +/- 6 in the moderate, and 6 +/- 5 in the low-risk group (p < 0.05). Based on the extent of coronary artery disease and results of thallium imaging, patients were reclassified into three groups: group 1 had three-vessel disease and/or > or = 10 abnormal segments (n = 387), group 3 had no coronary artery disease or one-vessel disease and less than five abnormal segments (n = 212), and the remaining patients were in group 2 (n = 235).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1462918     DOI: 10.1016/0002-8703(92)90076-8

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  8 in total

1.  Treadmill test scores: attributes and limitations.

Authors:  L J Shaw; R Hachamovitch; A E Iskandrian
Journal:  J Nucl Cardiol       Date:  1997 Jan-Feb       Impact factor: 5.952

2.  Effects of therapy with beta-blocker agents on myocardial perfusion and outcome.

Authors:  Deval Mehta; Ami E Iskandrian
Journal:  J Nucl Cardiol       Date:  2003 Jul-Aug       Impact factor: 5.952

3.  Using an outcomes-based approach to identify candidates for risk stratification after exercise treadmill testing.

Authors:  L J Shaw; R Hachamovitch; E D Peterson; H C Lewin; A E Iskandrian; D D Miller; D S Berman
Journal:  J Gen Intern Med       Date:  1999-01       Impact factor: 5.128

4.  Comparison of the treadmill exercise score and single-photon emission computed tomographic thallium imaging in risk assessment.

Authors:  A S Iskandrian; J Johnson; T T Le; V Wasserleben; V Cave; J Heo
Journal:  J Nucl Cardiol       Date:  1994 Mar-Apr       Impact factor: 5.952

5.  Outcome of patients with high-risk Duke treadmill score and normal myocardial perfusion imaging on spect.

Authors:  João V Vítola; Mauro R B Wanderley; Rodrigo J Cerci; Carlos C Pereira Neto; Otávio Kormann; Olímpio França Neto; José Antônio da Silva; Cláudio L Pereira da Cunha; Isabella Shin-Ike; Arnaldo L Stier
Journal:  J Nucl Cardiol       Date:  2015-06-03       Impact factor: 5.952

Review 6.  Assessing patients with possible heart disease using scores.

Authors:  K Shetler; A Karlsdottir; V Froelicher
Journal:  Sports Med       Date:  2001       Impact factor: 11.136

7.  Diagnostic value and incremental contribution of bicycle exercise, first-pass radionuclide angiography, and 99mTc-labeled sestamibi single-photon emission computed tomography in the identification of coronary artery disease in patients without infarction.

Authors:  A S Hambÿe; A Vervaet; S Lieber; R Ranquin
Journal:  J Nucl Cardiol       Date:  1996 Nov-Dec       Impact factor: 5.952

8.  Impact on exercise single-photon emission computed tomographic thallium imaging on patient management and outcome.

Authors:  N Nallamothu; S B Pancholy; K R Lee; J Heo; A S Iskandrian
Journal:  J Nucl Cardiol       Date:  1995 Jul-Aug       Impact factor: 5.952

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.